Literature DB >> 30606657

MET Immunohistochemistry Should Be Avoided in Selecting Non-small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis.

Laetitia Lambros1, Arnaud Uguen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30606657     DOI： 10.1016/j.cllc.2018.12.002

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  2 in total

1.  MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.

Authors:  Robin Guo; Lynne D Berry; Dara L Aisner; Jamie Sheren; Theresa Boyle; Paul A Bunn; Bruce E Johnson; David J Kwiatkowski; Alexander Drilon; Lynette M Sholl; Mark G Kris
Journal:  J Thorac Oncol       Date:  2019-06-20       Impact factor: 15.609

Review 2.  MET-dependent solid tumours - molecular diagnosis and targeted therapy.

Authors:  Robin Guo; Jia Luo; Jason Chang; Natasha Rekhtman; Maria Arcila; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2020-06-08       Impact factor: 66.675
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.